Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GSK221149 Clear all
Terminated Phase 3 Interventional Results available

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

NCT02377466
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban IV infusion, Placebo IV infusion
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 5, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole

NCT01627587
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
GSK221149 750 mg, Ketoconazole, GSK221149 100 mg, GSK221149 750 mg Fasted, GSK221149 750 mg + Food
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 5, 2026, 10:41 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects

NCT00449709
View directory record Official record
Conditions
Obstetric Labour, Premature, Premature Ejaculation
Interventions
GSK221149
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 5, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)

NCT01867996
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, EFZ 600 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 5, 2026, 10:41 AM EDT